市場調查報告書
商品編碼
1470458
生物模擬市場:按產品、交付模式、最終用戶、應用分類 - 2024-2030 年全球預測Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年生物模擬市場規模為38.1億美元,預計2024年將達44億美元,2030年將達98.7億美元,複合年成長率為14.55%。
生物模擬結合了數學、生物學和電腦程式設計來創建模擬來檢驗假設、預測結果並探索生物技術的新可能性。生物模擬透過模擬基因表現、新陳代謝和細胞生長等生物現象,幫助研究人員更好地了解生命的複雜性並開發醫療保健新產品。隨著新藥和藥品開發的不斷進步,以及政府專注於將數位化位技術整合到製藥和生物製藥領域,對生物模擬系統的需求不斷增加。然而,開發模擬軟體的高成本阻礙了市場的成長。由於電腦輔助設計(CAD)和虛擬實境(VR)技術的日益融合,以及人工智慧(AI)和機器學習(ML)在新模擬軟體開發中的進步,生物模擬市場預計將擴大馬蘇。
主要市場統計 | |
---|---|
基準年[2023] | 38.1億美元 |
預測年份 [2024] | 44億美元 |
預測年份 [2030] | 98.7億美元 |
複合年成長率(%) | 14.55% |
生物模擬軟體為模型建構、模擬、分析和視覺化提供平台,其使用正在不斷增加。
合約服務由專業公司和研究組織提供,為其客戶提供生物模擬專業知識,支援模型開發、模擬研究、資料分析和解釋。內部服務是在組織或研究機構內執行的生物模擬服務。分子建模和模擬軟體專注於對蛋白質、核酸和小分子等分子的行為進行模擬和建模。它用於研究分子之間的相互作用和結構變化,並預測結合親和性等特性。 PBPK建模和模擬軟體旨在模擬藥物和化學物質的生物分佈、吸收、代謝和排泄。 PK/PD、建模和模擬軟體影響藥物的藥物動力學和動態特性,幫助預測藥物濃度和暴露-反應關係,並最佳化給藥方案。毒性預測軟體專注於預測化合物的潛在毒性。計算模型用於評估接觸特定化學物質和藥物的安全性和潛在風險。臨床試驗設計軟體支援臨床試驗設計和最佳化,模擬各種臨床試驗場景,評估統計功效,最佳化樣本大小,以提高臨床試驗的效率和有效性。
交付模型:生物模擬傾向於支援為使用者提供完全控制的所有權模型。
生物模擬的所有權模型允許使用者購買軟體和服務,並完全控制軟體及其使用方式。在生物模擬所有權模型中,使用者購買軟體的永久許可證,並被授予無限期使用該軟體的權利。在訂閱模式中,使用者支付經常性費用才能存取和使用軟體和服務。在此模型中,使用者通常不擁有該軟體,但可以持續存取最新版本和更新。
最終用戶:製藥和生物技術公司擴大採用生物模擬
委外研發機構(CRO) 經常利用生物模擬來支援客戶的藥物發現和研發流程,包括使用生物模擬技術進行分子建模、PK/PD 建模、毒性預測等。製藥和生物技術公司在其藥物開發平臺中廣泛採用生物模擬。包括美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 在內的監管機構在核准藥品上市之前評估藥品的安全性和有效性方面發揮著重要作用。監管機構使用生物模擬來評估藥物的風險效益狀況、最佳化研究設計並在醫藥品認證過程中做出明智的決定。學術機構和政府機構等研究組織使用生物模擬來提高科學知識並進行高級研究。研究人員使用生物模擬工具和技術來建模和模擬複雜的生物系統,探索假設,並深入了解基本的生物過程。
將生物模擬的應用擴展到應用藥物開發
生物模擬提供有關藥物的藥物動力學 (PK) 和動態(PD) 特性的見解和預測,以最佳化給藥方案、預測目標組織中的藥物濃度以及候選藥物的潛在功效和安全性,它在藥物開發中發揮重要作用。 PBPK 和 PK/PD 建模等生物模擬技術可支援藥物開發中的明智決策。生物模擬支持臨床試驗的設計和最佳化,並能夠預測和評估藥物和化合物的吸收、分佈、代謝、排泄和毒性特性。生物模擬可以在藥物開發過程的早期識別潛在的 ADME/Tox 問題,從而減少廣泛的動物測試的需要並提供對潛在風險的洞察。 PK/PD建模和模擬可以預測藥物暴露和反應性之間的關係。生物模擬透過採用分子建模和模擬技術來支持先導化合物的識別和最佳化。幫助篩檢和評估潛在的候選藥物,預測與目標分子的結合親和性,並最佳化化學結構以提高效力和選擇性。生物模擬技術可以幫助識別和檢驗潛在的藥物標靶。生物模擬透過建模和模擬藥物分子與目標蛋白之間的相互作用,有助於評估靶向特定蛋白的可行性和潛在有效性。
區域洞察
美洲地區是生物模擬市場高度發展的地區。這是由於美國現有主要參與者的存在以及他們對推進模擬軟體的持續努力。 FDA(美國食品藥物管理局)、EMA(歐洲藥品管理局)和加拿大衛生署等監管機構的成立,確保藥物開發和臨床試驗的安全性和效率,為亞太地區的市場成長做出貢獻。 。就歐洲、中東和非洲地區而言,英國、德國和法國對藥物開發和臨床試驗的投資增加正在推動模擬軟體和服務的採用。亞太地區慢性病的增加預計將促使各國政府和監管機構加強對藥物開發的資助力度,為生物模擬市場的開拓提供平台。針對藥物研發 (R&D) 活動的各種舉措的存在,例如澳洲藥物發現計劃和醫學研究商業化計劃,正在擴大生物模擬在亞太地區的使用。
FPNV定位矩陣
FPNV定位矩陣對於評估生物模擬市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對生物模擬市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.生物模擬市場的市場規模與預測是多少?
2.在生物模擬市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.生物模擬市場的技術趨勢和法規結構是什麼?
4.生物模擬市場主要廠商的市場佔有率為何?
5. 進入生物模擬市場的合適型態和策略手段是什麼?
[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.
Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.81 billion |
Estimated Year [2024] | USD 4.40 billion |
Forecast Year [2030] | USD 9.87 billion |
CAGR (%) | 14.55% |
Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.
Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.
End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.
Application: Increasing application of biosimulation for drug development
Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.
Regional Insights
The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Biosimulation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?
3. What are the technology trends and regulatory frameworks in the Biosimulation Market?
4. What is the market share of the leading vendors in the Biosimulation Market?
5. Which modes and strategic moves are suitable for entering the Biosimulation Market?